Due to the current coronavirus pandemic, health systems all over the world are under pressure and need to prioritize resources very carefully. This special situation has affected Enroll-HD and some study sites have had to postpone Enroll-HD visits due to restrictions from local authorities, institutional policy changes, or lack of capacity to provide non-Covid-19-related services. Other study sites are continuing Enroll-HD visits. Your study site will notify you about any upcoming visits. Study visits will resume as soon as the situation allows. If permitted by local authorities and/or institutional policy, Enroll-HD management is advising study sites to give priority to study visits for interventional HD trials over Enroll-HD. This means that, if possible, ongoing clinical trials—for instance Roche’s GENERATION HD1 and Wave Life Sciences’ PRECISION-HD1 and 2—will be prioritized under the current pandemic situation.
Please contact your study site if you have concerns about your next Enroll-HD visit. Rest assured that Enroll-HD at your clinical site will be up and running normally as soon as possible.
If you are a participant in one of the interventional clinical trials that is testing a new drug, please contact your study site for more information and direction.